RxDoctor Payments Data

Jeffrey Suchniak, MD

Dermatology · Rocky Mount, NCNPI 1992799456

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,232 of the $6,526 with a category attached, or 64.8%. 20 manufacturers reported payments, led by Sanofi at 25.9% of the total. Reporting peaked in 2020 at $3,117 and has fallen 84.1% since, to $496 in 2025.

$6,526in general payments, 2019–2025

Across 123 payments — averaging $53.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$2K
  • UCB GmbH$1K
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$1K
  • AbbVie$731
  • Almirall LLC$423
  • Journey Medical Corporation$288
  • plus $1K from 14 others
$341,017in research payments, 2019–2025

Across 55 payments — averaging $6200.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • UCB SA$158K
  • Eli Lilly$110K
  • Pfizer$29K
  • Janssen Research & Development, LLC$22K
  • AbbVie$11K
  • UCB Biosciences Inc.$11K
  • plus $2K from 1 others

What the payments were for

  • Consulting fees$1,35321%
  • Travel & lodging$83613%
  • Food & beverage$4,23265%
  • Education$1052%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,526 in reported general payments places this provider in the 75th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$402,505
Medicare patients
1,286
Services billed
8,412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa23$513,248
Cosentyx Sensoready (2 Pens)Secukinumab20$171,708
Humira(Cf) PenAdalimumab13$128,927
Dupixent PenDupilumab25$100,403
Humira PenAdalimumab13$88,550
Dupixent SyringeDupilumab14$81,600
Metronidazole192$11,560
Fluocinolone Acetonide145$9,673
Acitretin21$8,703
Clobetasol Propionate228$8,336
Ketoconazole252$5,630
Mometasone Furoate179$4,275
Pimecrolimus14$3,562
Clindamycin Phosphate62$3,404
Fluorouracil36$3,216

Paid to pharmacies, not to this prescriber.

Other dermatology in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →